person
Richard S.
- Country
- Germany
- Department
- Medical Oncology
Research Overview
assignment
7
Clinical Trials ·
- MRD-Guided Pembrolizumab and Azacitidine Therapy in NPM1-Mutated Acute Myeloid Leukemia with Imminent Hematological Relapse
- Phase 2 Randomized, Blinded, Placebo-Controlled Study of INBRX-109 in Adults with Unresectable or Metastatic Conventional Chondrosarcoma
- Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
35
Sites with multiple studies
Has run more than one trial at 35 of 184 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute myeloid leukemia, with particular focus on patients with NPM1 mutations and molecular relapse monitoring.
- Molecular-guided therapy approaches
- Combination immunotherapy strategies
- Minimal residual disease management
Solid Tumor Oncology
Expertise extends to multiple solid tumor types, including rhabdomyosarcoma, chondrosarcoma, and prostate cancer.
- Advanced bone and soft tissue sarcomas
- Castration-resistant prostate cancer
- Novel bispecific antibody therapeutics
Precision Medicine
Focus on personalized cancer treatment approaches, particularly in BRAF-mutated malignancies and targeted therapy development.
- Molecular-based treatment selection
- Basket trial methodologies
- Biomarker-driven therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.